Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1520274
This article is part of the Research Topic Advances in Nanoparticles for Improving Current Anticancer Therapies by Targeting Cancer Stem Cells View all articles

Hyaluronic acid (HA)-targeted topotecan liposomes improve therapeutic efficacy against lung cancer in animals

Provisionally accepted
Gangqiang Xue Gangqiang Xue 1*Lu Tang Lu Tang 2*Xinyan Pan Xinyan Pan 3*Sanni Li Sanni Li 4*Juan Zhao Juan Zhao 5*
  • 1 Department of Pharmaceutic Preparation, Shijiazhuang Fourth Hospital, Shijiazhuang, Hebei Province, China
  • 2 Institute of Food Science and Technology, Chinese Academy of Agricultural Sciences, Beijing, China
  • 3 Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei Province, China
  • 4 Department of Pharmacy, Hebei Provincial Children's Hospital, Shijiazhuang, Hebei Province, China
  • 5 Experimental Center for Teaching, Hebei Medical University, Shijiazhuang, Hebei Province, China

The final, formatted version of the article will be published soon.

    Lung cancer, as a serious threat to human health and life, necessitating urgent treatment and intervention. In this study, we prepared hyaluronic acid (HA)-targeted topotecan liposomes for site-specific delivery to tumor cells. The coupling efficiency of HA on the surface of PEG-coated liposomes was determined to be 13.65 nmol/mg of lipid. The HA-targeted topotecan liposomes demonstrated a high encapsulation efficiency of 95% for topotecan, with an average particle size of 98.26 nm and excellent storage and dispersion stability. Drug release and cellular experiments indicated that the coating of HA further reduced the release rate of topotecan and decreased the survival rate of A549 cells, respectively. Flow cytometry and fluorescence staining analyses revealed that the HA-targeted topotecan liposomes enhanced the uptake of topotecan and exhibited significant anti-tumor effects on A549 cancer cells transplanted in mice. H&E staining showed that the pathological tissue treated with HA-targeted topotecan liposomes corresponded to Miller-Payne grade IV. Furthermore, these liposomes increased the accumulation of topotecan in tumors and extended the blood circulation time of the drug. Therefore, HA-targeted topotecan liposomes can be used as a new and easily prepared carrier in the field of lung chemotherapy, demonstrating considerable potential for anti-tumor therapy.

    Keywords: Hyaluronidase, Topotecan, Liposomes, lung cancer, pharmacokinetics

    Received: 31 Oct 2024; Accepted: 02 Dec 2024.

    Copyright: © 2024 Xue, Tang, Pan, Li and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Gangqiang Xue, Department of Pharmaceutic Preparation, Shijiazhuang Fourth Hospital, Shijiazhuang, Hebei Province, China
    Lu Tang, Institute of Food Science and Technology, Chinese Academy of Agricultural Sciences, Beijing, China
    Xinyan Pan, Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei Province, China
    Sanni Li, Department of Pharmacy, Hebei Provincial Children's Hospital, Shijiazhuang, Hebei Province, China
    Juan Zhao, Experimental Center for Teaching, Hebei Medical University, Shijiazhuang, 050017, Hebei Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.